Literature DB >> 6111854

Analysis of ranitidine in serum by high performance liquid chromatography.

H M Vandenberghe, S M MacLeod, W A Mahon, P A Lebert, S J Soldin.   

Abstract

We describe a simple and rapid micro method for the high pressure liquid chromatographic analysis of ranitidine, N-[2[[[5-[(dimethylamino)-methyl]-2-furanyl]methyl]thio]-ethyl-N'-methyl-2-nitro-1,1-ethenediamine in serum or plasma. The percentage analytical recovery of ranitidine and internal standard (metiamide) was 99% and 81%, respectively. The between-day precision of the procedure (n = 20) at ranitidine plasma concentrations of 500, 250, and 125 microgram/liter generated coefficients of variation of 6.2, 8.7, and 8.9%, respectively. The method was applied in preliminary studies to correlate serum concentrations of ranitidine with gastric acid secretion after continuous pentagastrin stimulation (2 microgram/kg/hr) in patients receiving an oral dose of 20, 40, or 80 mg of the drug.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6111854

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

1.  Effect of aluminum phosphate on the bioavailability of ranitidine.

Authors:  H Albin; G Vinçon; B Begaud; C Bistue; P Perez
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCl in volunteers.

Authors:  C Alioth; R A Blum; D T D'Andrea; G M Kochak; L Teng; B A Ziehmer; J J Schentag; K K Chan
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

3.  Ranitidine does not alter pethidine disposition in man.

Authors:  D R Guay; R C Meatherall; J L Chalmers; G R Grahame; R J Hudson
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

4.  Cimetidine-resistant Zollinger-Ellison syndrome: successful management with ranitidine.

Authors:  F M Habal; S J Soldin; G R Greenberg
Journal:  Can Med Assoc J       Date:  1983-08-01       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.